vs
Side-by-side financial comparison of Sensus Healthcare, Inc. (SRTS) and TECOGEN INC. (TGEN). Click either name above to swap in a different company.
TECOGEN INC. is the larger business by last-quarter revenue ($5.3M vs $4.9M, roughly 1.1× Sensus Healthcare, Inc.). Sensus Healthcare, Inc. runs the higher net margin — -64.1% vs -75.1%, a 11.0% gap on every dollar of revenue. On growth, TECOGEN INC. posted the faster year-over-year revenue change (-12.5% vs -62.2%). Sensus Healthcare, Inc. produced more free cash flow last quarter ($-2.4M vs $-2.6M). Over the past eight quarters, TECOGEN INC.'s revenue compounded faster (-7.3% CAGR vs -31.9%).
Sensus Healthcare, Inc. is a medical technology company that designs, manufactures and commercializes innovative non-invasive superficial radiation therapy systems. Its products are primarily used for treating non-melanoma skin cancers, keloids, and select cosmetic dermatology conditions, serving healthcare providers and clinical facilities worldwide.
SRTS vs TGEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.9M | $5.3M |
| Net Profit | $-3.2M | $-4.0M |
| Gross Margin | 38.4% | 36.8% |
| Operating Margin | -63.8% | -77.8% |
| Net Margin | -64.1% | -75.1% |
| Revenue YoY | -62.2% | -12.5% |
| Net Profit YoY | -304.9% | -236.7% |
| EPS (diluted) | $-0.19 | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.9M | $5.3M | ||
| Q3 25 | $6.9M | $7.2M | ||
| Q2 25 | $7.3M | $7.3M | ||
| Q1 25 | $8.3M | $7.3M | ||
| Q4 24 | $13.1M | $6.1M | ||
| Q3 24 | $8.8M | $5.6M | ||
| Q2 24 | $9.2M | $4.7M | ||
| Q1 24 | $10.7M | $6.2M |
| Q4 25 | $-3.2M | $-4.0M | ||
| Q3 25 | $-943.0K | $-2.1M | ||
| Q2 25 | $-1.0M | $-1.5M | ||
| Q1 25 | $-2.6M | $-659.9K | ||
| Q4 24 | $1.5M | $-1.2M | ||
| Q3 24 | $1.2M | $-930.4K | ||
| Q2 24 | $1.6M | $-1.5M | ||
| Q1 24 | $2.3M | $-1.1M |
| Q4 25 | 38.4% | 36.8% | ||
| Q3 25 | 39.4% | 30.4% | ||
| Q2 25 | 39.7% | 33.8% | ||
| Q1 25 | 52.2% | 44.3% | ||
| Q4 24 | 54.4% | 45.0% | ||
| Q3 24 | 59.3% | 44.1% | ||
| Q2 24 | 58.7% | 44.0% | ||
| Q1 24 | 62.5% | 41.6% |
| Q4 25 | -63.8% | -77.8% | ||
| Q3 25 | -37.3% | -29.2% | ||
| Q2 25 | -26.6% | -19.4% | ||
| Q1 25 | -31.7% | -8.2% | ||
| Q4 24 | 13.2% | -18.7% | ||
| Q3 24 | 16.9% | -15.5% | ||
| Q2 24 | 21.5% | -31.2% | ||
| Q1 24 | 27.1% | -17.0% |
| Q4 25 | -64.1% | -75.1% | ||
| Q3 25 | -13.7% | -29.7% | ||
| Q2 25 | -14.2% | -20.1% | ||
| Q1 25 | -30.8% | -9.1% | ||
| Q4 24 | 11.8% | -19.5% | ||
| Q3 24 | 13.7% | -16.5% | ||
| Q2 24 | 17.4% | -32.5% | ||
| Q1 24 | 21.3% | -17.9% |
| Q4 25 | $-0.19 | $-0.14 | ||
| Q3 25 | $-0.06 | $-0.07 | ||
| Q2 25 | $-0.06 | $-0.06 | ||
| Q1 25 | $-0.16 | $-0.03 | ||
| Q4 24 | $0.10 | $-0.05 | ||
| Q3 24 | $0.07 | $-0.04 | ||
| Q2 24 | $0.10 | $-0.06 | ||
| Q1 24 | $0.14 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $12.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $21.6M |
| Total Assets | $53.0M | $37.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $12.4M | ||
| Q3 25 | $24.5M | $15.3M | ||
| Q2 25 | $22.2M | $1.6M | ||
| Q1 25 | $19.1M | $4.1M | ||
| Q4 24 | $22.1M | $5.4M | ||
| Q3 24 | $22.6M | $1.3M | ||
| Q2 24 | $19.0M | $841.9K | ||
| Q1 24 | $14.7M | $1.5M |
| Q4 25 | $48.1M | $21.6M | ||
| Q3 25 | $51.2M | $25.5M | ||
| Q2 25 | $52.1M | $9.1M | ||
| Q1 25 | $53.0M | $9.6M | ||
| Q4 24 | $55.8M | $10.2M | ||
| Q3 24 | $54.1M | $11.3M | ||
| Q2 24 | $52.9M | $12.2M | ||
| Q1 24 | $51.2M | $13.7M |
| Q4 25 | $53.0M | $37.0M | ||
| Q3 25 | $58.3M | $41.5M | ||
| Q2 25 | $58.9M | $28.4M | ||
| Q1 25 | $60.2M | $29.7M | ||
| Q4 24 | $62.2M | $31.1M | ||
| Q3 24 | $59.9M | $27.5M | ||
| Q2 24 | $58.2M | $27.2M | ||
| Q1 24 | $57.3M | $28.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.2M | $-2.6M |
| Free Cash FlowOCF − Capex | $-2.4M | $-2.6M |
| FCF MarginFCF / Revenue | -47.9% | -49.3% |
| Capex IntensityCapex / Revenue | 3.2% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $332.0K | $-10.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.2M | $-2.6M | ||
| Q3 25 | $2.3M | $-3.6M | ||
| Q2 25 | $3.1M | $-2.6M | ||
| Q1 25 | $-2.7M | $-1.2M | ||
| Q4 24 | $-827.0K | $4.2M | ||
| Q3 24 | $4.0M | $-207.3K | ||
| Q2 24 | $4.2M | $-157.9K | ||
| Q1 24 | $-8.2M | $248.2K |
| Q4 25 | $-2.4M | $-2.6M | ||
| Q3 25 | $2.3M | $-3.6M | ||
| Q2 25 | $3.1M | $-2.7M | ||
| Q1 25 | $-2.7M | $-1.3M | ||
| Q4 24 | $-1.1M | $4.0M | ||
| Q3 24 | $3.6M | $-489.6K | ||
| Q2 24 | $4.2M | $-609.6K | ||
| Q1 24 | $-8.4M | $143.3K |
| Q4 25 | -47.9% | -49.3% | ||
| Q3 25 | 33.3% | -50.6% | ||
| Q2 25 | 42.2% | -37.7% | ||
| Q1 25 | -32.2% | -17.9% | ||
| Q4 24 | -8.6% | 66.6% | ||
| Q3 24 | 40.9% | -8.7% | ||
| Q2 24 | 45.8% | -12.9% | ||
| Q1 24 | -79.0% | 2.3% |
| Q4 25 | 3.2% | 0.9% | ||
| Q3 25 | 0.1% | 1.0% | ||
| Q2 25 | 0.4% | 2.0% | ||
| Q1 25 | 0.1% | 1.8% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 3.8% | 5.0% | ||
| Q2 24 | 0.0% | 9.6% | ||
| Q1 24 | 2.2% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.53× | — | ||
| Q3 24 | 3.25× | — | ||
| Q2 24 | 2.62× | — | ||
| Q1 24 | -3.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SRTS
| Products | $2.8M | 57% |
| Other | $2.1M | 43% |
TGEN
| Installation Services | $4.5M | 84% |
| Products Segment | $460.5K | 9% |
| Other | $394.7K | 7% |
